Davies Veterinary Specialists, Higham Gobion, Hitchin, SG5 3HR, UK.
Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, 30559, Hannover, Germany.
BMC Vet Res. 2022 Mar 7;18(1):88. doi: 10.1186/s12917-022-03182-y.
Meningioma is the most common primary brain neoplasm in dogs. Further information is required regarding the expected long-term prognosis of dogs following the surgical resection of an intracranial meningioma together with the influence of adjunctive therapies. Whilst there have been several studies reporting the long-term outcome of intracranial meningioma resection following surgery alone, surgery with the use of an ultrasonic aspirator, surgery combined with radiotherapy and surgery combined with the addition of hydroxyurea, it is currently unclear which type of adjunctive therapy is associated with the most favourable outcomes. The objective of this study is to describe the presentation and outcome of dogs undergoing surgery for the resection of an intracranial meningioma and the effect of clinical factors, adjunctive therapies and meningioma histopathological subtype on the long-term outcome.
A hundred and one dogs that had intracranial surgery for meningioma resection were investigated from four referral centres. 94% of dogs survived to hospital discharge with a median survival time of 386 days. Approximately 50% of dogs survived for less than a year, 25% survived between 1 and 2 years, 15% survived between 2 and 3 years and 10% survived for greater than 3 years following discharge from hospital. One or more adjunctive therapies were used in 75 dogs and the analysis of the data did not reveal a clear benefit of a specific type of adjunctive therapy. Those dogs that had a transfrontal approach had a significantly reduced survival time (MST 184 days) compared to those dogs that had a rostrotentorial approach (MST 646 days; p < 0.05). There was no association between meningioma subtype and survival time.
This study did not identify a clear benefit of a specific type of adjunctive therapy on the survival time. Dogs that had a transfrontal approach had a significantly reduced survival time. Intracranial surgery for meningioma resection offers an excellent prognosis for survival to discharge from hospital with a median long term survival time of 386 days.
脑膜瘤是犬最常见的原发性脑肿瘤。对于接受颅内脑膜瘤切除术后的犬，需要进一步了解其长期预后，以及辅助治疗的影响。虽然有几项研究报告了单独手术、使用超声吸引器手术、联合放疗手术和联合羟基脲手术切除颅内脑膜瘤的长期结果，但目前尚不清楚哪种辅助治疗与最佳结果相关。本研究旨在描述接受颅内脑膜瘤切除术的犬的表现和结果，以及临床因素、辅助治疗和脑膜瘤组织病理学亚型对长期结果的影响。
从四家转诊中心调查了 101 只接受颅内手术切除脑膜瘤的犬。94%的犬在出院时存活，中位生存时间为 386 天。大约 50%的犬存活不到一年，25%存活 1 至 2 年，15%存活 2 至 3 年，10%存活超过 3 年。75 只犬使用了一种或多种辅助治疗方法，但数据分析并未显示特定类型辅助治疗的明显益处。接受额前入路的犬的生存时间明显缩短（MST 为 184 天），而接受额后入路的犬的生存时间明显延长（MST 为 646 天；p<0.05）。脑膜瘤亚型与生存时间之间无关联。
本研究未发现特定类型辅助治疗对生存时间有明显益处。接受额前入路的犬生存时间明显缩短。颅内脑膜瘤切除术可为犬提供极好的预后，出院时的中位长期生存时间为 386 天。
